Mili Nadipalli represents clients facing a variety of antitrust and competition challenges, including government investigations, filing obligations under the Hart-Scott-Rodino Act, complex civil litigation, and client counseling in relation to antitrust issues. Her industry experience includes pharmaceuticals, consumer products, entertainment, retail, agriculture, transportation, and healthcare.
Mili received her J.D. from Washington University in St. Louis School of Law, where she served as chief articles editor of the Washington University Law Review. During law school, she was a semester extern in the Media, Entertainment, and Communications Section of the DOJ’s Antitrust Division and a summer intern at the U.S. Attorney’s Office for the District of Columbia.
Experience
- Pfizer in its US$43 billion acquisition of Seagen Inc., a world-leader in antibody-drug conjugates (ADCs).
- AbbVie in its US$8.7 billion acquisition of Cerevel Therapeutics.
- Boston Scientific in its US$3.7 billion acquisition of Axonics, Inc.
Perspectives
Credentials
Education
- J.D., Washington University in St. Louis School of Law, 2022
- B.S., Neuroscience, College of William and Mary, 2018
Admissions
- District of Columbia
Activities
- Member, ABA Antitrust Law Section